Furthermore, evidence shows that the tumor microenvironment drives function exhaustion in a subset of CD8 + T-cells, conditioning cell surface expression of CD39, an immunosuppressive molecule that can be therapeutically targeted to restore the effector T-cell function [54]. This evidence concerns the gene CD8A and neoplasm.